Cloudbreak Therapeutics, LLC

Quick facts

Phase 3 pipeline

• CBT-001
  CBT-001 is a therapeutic candidate in development by Cloudbreak Therapeutics, but its specific mechanism of action is not publicly disclosed.

Phase 2 pipeline

• CBT-001 Multi-dose
• CBT-001 single dose · Oncology
  CBT-001 is a small molecule that targets the CD47/SIRPα axis.
• CBT-004 · Oncology
  CBT-004 is a T cell engager designed to redirect patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.
• CBT-006
• CBT-008

Phase 1 pipeline

• CBT-009

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cloudbreak Therapeutics, LLC portfolio CI brief
• Cloudbreak Therapeutics, LLC pipeline updates RSS